Home/ Stocks/ XFOR

X4 Pharmaceuticals, Inc. Common Stock

XFOR XNAS

$4.64 +0.26 (+6.24%) ▲ 15-min delayed

Open

$4.26

High

$4.82

Low

$4.21

Volume

1.60M

Market Cap

$393.31M

About X4 Pharmaceuticals, Inc. Common Stock

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 45 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.50M	$-20,241,000	$-0.16
Q3 2025	$1.57M	$-29,815,000	$-0.69
Q2 2025	$1.74M	$-25,741,000	$-3.47
Q1 2025	$900.0K	$282.0K	$0.04

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for XFOR yet. Check out our latest market news or earnings calendar.

Get XFOR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on X4 Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.